Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals ≥ 65 years of age: a Danish cohort study

This study aimed to estimate the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against invasive pneumococcal disease (IPD) among individuals ≥ 65 years of age. We used Danish nationwide databases to obtain information on PPV23 vaccination, covariates, and IPD and linked...

Descripción completa

Detalles Bibliográficos
Autores principales: Nielsen, Katrine Finderup, Nielsen, Lise Birk, Lomholt, Frederikke Kristensen, Nørgaard, Sarah Kristine, Slotved, Hans-Christian, Dalby, Tine, Fuursted, Kurt, Jørgensen, Charlotte Sværke, Valentiner-Branth, Palle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593971/
https://www.ncbi.nlm.nih.gov/pubmed/36282341
http://dx.doi.org/10.1007/s10096-022-04513-5
Descripción
Sumario:This study aimed to estimate the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against invasive pneumococcal disease (IPD) among individuals ≥ 65 years of age. We used Danish nationwide databases to obtain information on PPV23 vaccination, covariates, and IPD and linked data on an individual level using a unique personal identifier. A total of 948,263 individuals were included and followed between June 15, 2020, and September 18, 2021 (58.6% were vaccinated during follow-up). The adjusted vaccine effectiveness was 42% (95% confidence interval (CI): 9–63%) for all-serotype IPD and 58% (95% CI: 21–78%) for PPV23-serotype IPD, using no vaccination as the reference. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10096-022-04513-5.

Ejemplares similares